Dermatitis herpetiformis is an autoimmune chronic blistering disease, considered a skin manifestation of celiac disease. Being both conditions multifactorial, they share some genetic traits and pathogenic mechanisms, which are responsible for the typical skin and gastrointestinal manifestations. In dermatitis herpetiformis, skin and other lesions heal after gluten-free diet and reappear shortly after its reintroduction to complete diet. Prevalence of celiac disease is 1% in the population, and approximately 13% of patients with the disease develop dermatitis herpetiformis. Diagnosis of celiac disease has progressively increased in recent decades, while clinical manifestations become more and more diverse. Given the current high frequency of skin lesions in celiac patients, in this review we update relevant aspects of the epidemiology, pathogenesis, clinical presentations, treatment and follow up of dermatitis herpetiformis, as a contribution to improve the management of both conditions.

Abstract: Glycogen storage diseases (GSD) are rare diseases derived from altered glycogen metabolism. This leads to glycogen storage in different organs such as muscle, kidney, and liver, resulting in a variety of clinical manifestations. GSD with liver involvement are classified into types I, III, IV, VI, and IX, depending on the enzymes affected. They are clinically characterized by hypoglycemia and hepato megaly as cardinal signs. Their diagnosis is initially based on clinical manifestations and laboratory test results. Nevertheless, diagnostic certainty requires a genetic study that identifies the specific mutation. Multiple mutations have been associated with each GSD. In Chile, since patients often lack the genetic study, the GSD genetic local characteristics are unknown. The treatment is based on dietary restrictions modulated according to the identified mutation. Today, the international consen sus indicates that early diagnosis allows better metabolic control and improves the patient's quality of life and prognosis. In this review, the information on GSD with liver involvement is updated to optimize the diagnosis, treatment, and follow-up of these patients, emphasizing specific nutritional and gastroenterological management.

Resumen: Las enfermedades por depósito de glucógeno (EDG) son un grupo de patologías de baja frecuencia, derivadas de la alteración del metabolismo del glucógeno, lo que lleva a que este se almacene en diferentes órganos como el músculo, riñón e hígado, produciendo distintas manifestaciones clínicas. Las EDG de compromiso hepático se clasifican en los tipos I, III, IV, VI y IX, dependiendo de las distintas enzimas afectadas. Se caracterizan clínicamente por hipoglicemia y hepatomegalia como síntomas cardinales. La sospecha diagnóstica se basa en las manifestaciones clínicas presentes y los resultados de los exámenes de laboratorio, pero el diagnóstico definitivo requiere un estudio genético que identifique la mutación subyacente. Se han descrito múltiples mutaciones para cada EDG. En la población chilena, se desconoce la caracterización genotípica de estas enfermedades. El tratamiento es dietético y se modula según la mutación presente. Hoy día hay amplio consenso en que un buen control metabólico permite mejorar la calidad de vida y el pronóstico de los pacientes. En esta revi sión se actualiza la información sobre las EDG que presentan compromiso hepático, para optimizar el diagnóstico, tratamiento y seguimiento de estos pacientes, dando énfasis al manejo específico nu tricional y gastroenterológico.

Abstract: Introduction: The lifelong gluten-free diet (GFD) is the treatment of celiac disease (CD). Being a restrictive diet, it limits daily life and can impact on the health-related quality of life (HRQoL). Our objective was to assess HRQoL of celiac patients on a GFD, the concordance between patients - caregivers, and to compare the local results with international data. Patients and Method: Patients aged 8-18 years on a GFD for >6months (37 dyads) were evaluated. The “Celiac Disease Dutch Questionnaire” (CDDUX) was applied, which evaluates in two questionnaires (one applied to the child and another one to the caregiver/parent), three areas: i) having CD, ii) communication with others, and iii) the diet. Reliability, dimensionality, and internal consistency were assessed using the Cronbach coefficient. Results: More than 50% of patients and caregivers reported “well/very well” on sub-scales “having CD” and “GFD”; “communication” showed high percentages of “bad/very bad”. Although there were no significant differences in HRQoL (global and subscale) perceived by patients and caregivers, there were when analyzing the answers of caregivers, who assigned better scores to boys (p=0.022) and to patients maintaining a non-strict GFD (p=0.049). Concordance between patients and caregivers was 39.2%. Discussion: HRQoL of the assessed celiac children was satisfactory, among the best repor ted in Latin America. “Having CD” and the need for a “GFD” have less influence on HRQoL than “communication” with others about the disease. The concordance found suggests that the caregivers’ perception does not necessarily reflect what patients perceive.

Resumen: Introducción: La dieta libre de gluten (DLG) de por vida es el tratamiento de la enfermedad celiaca (EC). Sien do una dieta restrictiva, impone limitaciones en la vida diaria y puede repercutir en la calidad de vida relacionada a la salud (CVRS). Nuestro objetivo fue evaluar la CVRS de pacientes celíacos en DLG, la concordancia entre pacientes-cuidador/a, y comparar la situación local con experiencias internacionales. Pacientes y Método: Se evaluaron pacientes de 8-18 años en DLG > 6 meses (37 diadas). Se les aplicó el “Celiac Disease Dutch Questionnaire” (CDDUX), que evalúa en 2 cuestio narios (uno al niño y otro al cuidador/padre), tres áreas: i) el tener EC, ii) la comunicación con otros y iii) la dieta. Se evaluó la confiabilidad, la dimensionalidad, y la consistencia interna mediante el coeficiente de Cronbach. Resultados: Más del 50% de los pacientes y cuidadores reportan bien/ muy bien en las sub-escalas “tener enfermedad” y “dieta libre de gluten”; “comunicación” mostró altos porcentajes de mal/muy mal. No hubo diferencias significativas en la CVRS percibida por pacientes y cuidadores (global y sub-escala). Sí las hubo al analizar las respuestas de las/los cuida dores, que asignaron mejores puntajes a los pacientes varones (p = 0,022) y a quienes seguían DLG de manera no estricta (p = 0,049). La concordancia entre pacientes y cuidadores fue 39,2%. Discu sión: La CVRS de los pacientes evaluados aparece como satisfactoria, de las mejores reportadas en latinoamericana. El manejo de “tener EC” y la necesidad de mantener una “DLG” influyen menos en la CVRS que el tener que comunicarse con otros acerca de la enfermedad. La concordancia encontrada sugiere que la percepción del cuidador/a no refleja necesariamente lo que percibe el paciente.

An increasing number of children and adults are currently suffering symptoms due to FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols) consumption. These carbohydrates are poorly digested in the human gastrointestinal tract, exerting an osmotic effect in the small intestine. In the colon, they become substrates to the microbiota. Microbial fermentation explains symptoms such as abdominal distention (postprandial fullness), bloating and flatulence, abdominal pain and loose feces or diarrhea. There are no standardized methods to measure them in daily clinical work. Daily tolerance and the no-effect doses are unclear. How to diagnose and treat FODMAP associated symptoms is also controversial. In this review, we aim to define FODMAP, their associated symptoms and the current techniques for assessing them. The low-FODMAP diet is described and how to implement it.

Abstract: Introduction: The worldwide prevalence of celiac disease (CD) is ~1% of the population. In Chile, the National Health Survey 2009-2010 showed a serological prevalence in individuals older than 15 years of 0.76% (IgA-tTG2), which corresponded in Concepción to 0.6%. Objective: Determine cli nical characteristics, search, diagnosis, treatment and follow-up of CD in the two public hospitals in Concepción that have a Gastroenterology Department. Patients and Method: Descriptive study. Data were collected from electronic medical records (CIE10 code) and medical records of patients youn ger than 18 years of age, assessed for CD during 2010 - 2016 from two public hospitals in the city of Concepción, Chile. Cases whose diagnostic protocol met the ESPGHAN 2012 criteria (confirmation with intestinal biopsy), 207 out of 216 identified patients met the inclusion criteria. The nutritional status was classified according to age group (in children under five years old by WHO 2006 and in children between five and 18 years old by WHO 2007). The Z-score (Z) was calculated using the WHO Anthro software (in children under five years old) and WHO Anthro Plus software (in those between five and 18 years old). Antiendomysial antibodies were assessed by immunofluorescence test in cuts of the esophagus of mono, IgA and IgG anti-transglutaminase antibodies via ELISA, as well as serum IgA. Results: CD was confirmed by duodenal biopsies in 33.8% of the patients. IgA-tTG was identified in 70% and IgG-tTG in 52.9%, although only two patients had IgA deficiency. The main reasons for consultation were gastrointestinal (80%) and/or referral by an endocrinologist (45.7%). The main clinical presentation was gastrointestinal, with diarrhea (71.4%). 17.1% of the patients had Down syndrome (DS), 11.4% short stature, and 5.7% had type 1 diabetes mellitus. At diagnosis, the obesity:malnutrition ratio (Z-score BMI) was 2:1 and 6.8% of the patients were obese. One year after diagnosis, in 26 patients without DS, the frequency of eutrophic patients decreased from 65.4% to 42.3%, increasing overweight from 23.1% to 34.6% and obesity from 0 to 7.7%. Conclusions: In Con cepción, endocrinologists conduct a significant and successful active search of CD, being responsible for 47.3% of the diagnoses. The high proportion of overweight/obese patients is consistent with the phenomenon currently described in Chile and other countries.

Resumen: Introducción: La prevalencia global de enfermedad celíaca (EC) es ~1% de la población. En Chile, la Encuesta Nacional de Salud 2009-2010 mostró una prevalencia serológica en mayores de 15 años de 0,76% (IgA-TTG2), que en Concepción correspondió a 0,6%. Objetivo: Determinar las caracte rísticas clínicas, de búsqueda, diagnóstico, tratamiento y seguimiento de la EC en los dos hospitales públicos de Concepción con servicio de Gastroenterología. Pacientes y Método: Estudio descriptivo, se recogieron datos de las fichas electrónicas (código CIE10) y clínicas de menores de 18 años estu diados por EC entre 2010 - 2016 provenientes de dos hospitales públicos de la ciudad de Concepción, Chile. Se identificaron los casos cuyo protocolo diagnóstico cumplía con los criterios ESPGHAN 2012 (confirmación con biopsia intestinal), 207 de 216 pacientes identificados cumplían los criterios de inclusión. El estado nutricional se clasificó según grupo etario (menores de 5 años OMS 2006; en los niños entre 5 y 18 años OMS 2007). Se calculó el Z-score (Z), a través del software WHO Anthro (en menores de 5 años) y WHO Anthro Plus (entre 5-18 años). Los anticuerpos antiendomisio se evaluaron mediante inmuno fluorescencia en cortes de esófago de mono; los anticuerpos antitrans- glutaminasa IgA e IgG a través ELISA; e IgA en sangre mediante ELISA. Resultados: Se confirmó EC por biopsias duodenales en 33,8%. IgA-TTG estuvo registrada en 70% e IgG-TTG en 52,9%, aunque solo dos pacientes tenían deficiencia de IgA. Los motivos de consulta preponderantes fueron gas trointestinales (80%) y/o derivación por un endocrinólogo (45,7%). La principal presentación clínica fue gastrointestinal, con diarrea (71,4%). El 17,1% presentaba Síndrome de Down (SD), 11,4% talla baja y 5,7% diabetes mellitus 1. Al diagnóstico, la relación obesidad: desnutrición (Z-score IMC) fue 2:1 y 6,8% de los pacientes eran obesos. Al año post-diagnóstico, en 26 pacientes celíacos sin SD la frecuencia de estado nutricional eutrófico disminuyó de 65,4% a 42,3%, aumentando el sobrepeso de 23,1 a 34,6% y la obesidad de 0 a 7,7%. Conclusiones: En Concepción, la especialidad de endo crinología efectúa una significativa y exitosa búsqueda activa, siendo responsable de 47,3% de los diagnósticos. La alta proporción de pacientes con sobrepeso/obesidad concuerda con el fenómeno descrito actualmente en Chile y otros países.

Abstract: Introduction: Celiac disease (CD) is a chronic immune-mediated enteropathy present in ~1% of population. Gluten-free diet (GFD) is the only treatment for this condition and the main limitation of its efficacy is the lack of adherence. Objective: To assess factors influencing adherence to GFD in pediatric patients and measure the concordance between serological results and a nutritional adhe rence questionnaire. Patients and Methods: celiac patients younger than 18 years of age, diagnosed CD following ESPGHAN criteria, on GFD for at least 6 months and consulting at Hospital Roberto del Río, Santiago, in 2008-2016, were assessed. Clinical presentation, nutritional evaluation and fac tors related to adherence to treatment (diet) were registered. A subsample answered Biaggi's nutri tional questionnaire. Results: Of 65 evaluated patients, 44% and 30,1% adhered to GFD according to blood autoantibodies (TTG and EMA) and the adherence questionnaire, respectively. “Age at debut” (p = 0.049), “perception of following GFD correctly” (p = 0.002) and “behavior in social events” (p = 0.005) were significantly associated with adherence to GFD. There was concordance between serological test and Biagi’s questionnaire (p = 0.0001). Discussion: Adherence to GFD was lower than reported in literature. Intervention of some of the identified variables associated with adherence may help improving follow-up of celiac patients, especially those that due to diverse situations cannot measure their antibodies periodically.

Resumen: Introducción: La enfermedad celíaca (EC) es una enteropatía crónica mediada inmunológicamente que afecta ~1% de la población. La dieta libre de gluten (DLG) es su único tratamiento y la princi pal limitante de su eficacia es la falta de adherencia. Objetivos: Evaluar factores que influyen en la adherencia a la DLG de pacientes celiacos pediátricos. Medir la concordancia entre la serología y un cuestionario nutricional de adherencia. Pacientes y Método: Estudio transversal en celiacos menores de 18 años, en DLG por más de 6 meses. Se aplicó un cuestionario con 5 grupos de factores (OMS). Se registraron características clínicas, dieta de los últimos 3 meses, percepción (de padres/cuidadores, y del paciente adolescente) de la DLG; el conocimiento de los alimentos permitidos y disponibles en el país de la simbología “libre de gluten”, y si lee/no lee ingredientes de un alimento antes de comprarlo. Se aplicó un score dando un punto a cada respuesta correcta (0-4). A un subgrupo se le aplicó el cues tionario de adherencia a la DLG de Biagi. Se midió EMA y TTG dentro de las 2 semanas posteriores a la entrevista. Se usó índice Kappa para evaluar la concordancia entre TTG y encuesta nutricional de adherencia; Chi cuadrado para la asociación entre los factores evaluados y los resultados de EMA y TTG, y Odds ratio como medida de asociación. Se aplicó un modelo de regresión logística a los factores asociados a los resultados de los exámenes de anticuerpos EMA y TTG (positivo-negativo). Se definió “buena adherencia a la DLG” cuando EMA y TTG fueron negativos. Resultados: De 65 pa cientes; 44% y 30,1% adherían correctamente a la DLG según medición de anticuerpos (TTG y EMA) y el cuestionario, respectivamente. La “edad de inicio de la enfermedad” (p = 0,049), “percepción de estar realizando bien la DLG” (p = 0,002) y la “conducta del paciente frente a alimentos en reuniones sociales” (p = 0,005), se asociaron significativamente con adherencia a DLG. Hubo concordancia entre los exámenes serológicos y el cuestionario de adherencia (p = 0,0001). Discusión: La adheren cia fue menor que la reportada en la literatura. La intervención de variables asociadas a adherencia identificadas, podría ayudar al mejor seguimiento de los pacientes, especialmente en aquellos quienes por diversos motivos no puedan realizarse exámenes serológicos con la frecuencia adecuada.

Coeliac disease (CD) is a systemic autoimmune disorder triggered by gluten consumption in genetically susceptible individuals. It exhibits several clinical features, such as blood auto-antibodies (anti-endomysial antibodies EMA, anti-transglutaminase antibodies tTG, anti-deamidated gliadin peptides PGD), plus variable degrees of damage in the small intestinal mucosa. In Chile, tTG is positive in 0.76% in individuals >15 years, with the prevalence of CD being estimated at 0.6%. Approximately17% of first-degree relatives of coeliac patients have been reported tTG positive. To date, the gluten free diet (GFD) is the only known treatment for CD. To be effective, this must be lifelong, permanent, and strict. Gluten content in the GFD is not zero, but is limited to a cut-off of 3 ppm (or mg/kg of product) in Chile. Mortality higher than that of the general population has been reported among coeliac patients, and poor adherence to GFD is associated with complications (mainly autoimmune processes and cancer). GFD is difficult to maintain strictly and poor adherence is by far the main cause of lack of response to treatment. Follow-up of adherence is also difficult because there are no objective measurements to assess it. In clinical practice determination of serum EMA, tTG and PGD is routinely used for these purposes, although more recently, the interview by an expert dietitian, validated questionnaires and measurement of faecal 33-mer peptide are being assessed as alternatives or complements to measure adherence to GFD. A review is presented with the current concepts on the available tools to follow up patients on GFD, emphasising those available in Chilel.

La enfermedad celíaca (EC) es un trastorno sistémico inmune mediado por la ingesta de gluten en individuos genéticamente susceptibles. Se caracteriza por manifestaciones clínicas variables, auto anticuerpos anti-endomisio, anti-transglutaminasa (tTG) y/o anti-péptidos de gliadina deamidados (PGD) en sangre, más daño variable de la mucosa intestinal. En Chile el 0,76% de los mayores de 15 años tiene IgA-tTG positiva y la prevalencia de EC se estima en ~0,6%. En familiares de primer grado de celíacos se ha identificado ~17% de casos tTG positivos. Hasta hoy el único tratamiento es la dieta libre de gluten (DLG), que para ser efectiva debe ser estricta, permanente y durante toda la vida. La DLG no contiene cero gluten, sino que lo disminuye hasta un «punto de corte», que en Chile es 3 ppm (o mg/kg de producto). La mortalidad de la EC es mayor que la de la población general, y la falta de adherencia al tratamiento se asocia a complicaciones (procesos autoinmunes y cáncer principalmente). La DLG es difícil de mantener estrictamente, y las transgresiones son por lejos la principal causa de falta de respuesta al tratamiento. El seguimiento también es difícil, porque no existen marcadores objetivables que midan la adherencia. En la práctica clínica se utiliza la medición de auto anticuerpos anti-endomisio, tTG y/o PGD; más recientemente se están evaluando las entrevistas por una nutricionista especializada, cuestionarios validados y la medición de péptidos 33-mer en heces como alternativas o complementos de la evaluación de adherencia. En este artículo se revisan las herramientas de seguimiento actualmente utilizadas, poniendo énfasis en aquellas disponibles en Chile.

The gluten-free foods global market has significantly grown during the last decade. Gluten-free diet represents the treatment for celiac disease, non-celiac gluten sensitivity and wheat allergy Another group of persons that follows gluten-free diet has emerged, perceiving this diet as healthier feeding habit. It is especially this latter group that has increased to such an extent that they modified the market of gluten-free foods, improving availability of these products. However, because their demands and requirements are different, gluten content control of many of the currently existing local gluten-free foods is unsatisfactory We present the information available on these issues, emphasizing the few local data available, which refer to school-age snacks and the "Basic Food Basket", with and without gluten. Local studies show that gluten-free snacks for school-age children and the gluten-free Basic Food Basket are less available, their cost is higher and less than 8% meet FAO/WHO nutritional recommendations.

El mercado global de los productos sin gluten ha tenido un aumento sin precedente en la última década. La dieta sin gluten constituye el tratamiento de la enfermedad celíaca, la sensibilidad no-celíaca al gluten y de la alergia al trigo. Recientemente ha aparecido otro grupo de personas que elimina el gluten por considerarlo una opción de alimentación más saludable. Es especialmente este último grupo que ha logrado mejorar el mercado de alimentos sin gluten, pero sus requerimientos son distintos, por lo que parte del aumento del mercado ha sido en base de productos sin control adecuado de su contenido de gluten. Analizamos la información existente, poniendo énfasis en los datos nacionales recientemente obtenidos acerca de las colaciones escolares y la Canasta Básica Familiar sin gluten. En ambos casos la disponibilidad de productos equivalentes sin gluten es menor, el costo tres o más veces mayor y menos del 8% de ellos cumplen las recomendaciones nutricionales de la FAO/OMS.

Celiac disease is a chronic systemic disorder mediated by immune and autoimmune phenomena, triggered by ingestion ofgluten and related prolaminas in genetically susceptible individuals. Food allergy is an adverse, immune mediated, reproducible reaction to a foodstuff. Recommendations on complementary feeding have varied along time and also vary in different countries, depending on their cultures, socioeconomic resources and dietary habits. To date the scientific evidence is not clear about how the nature and quantity of foods given to a child and the forms in which they are given influence health and futures development in the child. Recent publications question some basic criteria of pediatric feeding, like the protective role of maternal milk and the benefit of postponing the introduction of some frequently allergenic foods; they suggest that the age of introduction of gluten and other potentially allergenic foodstuffs do not modify the risk of developing celiac disease or food allergy and that breast feeding does not protect from these two conditions. For these reasons we have considered relevant to review the available evidence on these matters on celiac disease and food allergy.

La Enfermedad Celíaca (EC) es una enfermedad sistémica crónica mediada por fenómenos inmunes y autoinmunes, gatillado por la ingesta de gluten y prolaminas relacionadas, en individuos genéticamente susceptibles. La alergia alimentaria (AA) es una reacción adversa, inmuno-mediada, reproducible a un alimento. Las recomendaciones acerca de la alimentación complementaria han variado a lo largo del tiempo y también varían en los distintos países según sus culturas, medios económicos y hábitos alimentarios. Hasta el momento la evidencia científica no entrega certeza en cómo la naturaleza de los alimentos entregados, la cantidad de éstos o la forma de darlos, influyen en la salud y desarrollo a futuro del niño. Estudios publicados recientemente han puesto en duda algunos criterios básicos de la alimentación en pediatría, como el rol protector de la lactancia materna o el beneficio de retardar la introducción de ciertos alimentos frecuentemente alergénicos, sugiriendo que la edad de introducción del gluten y otros alimentos potencialmente alergénicos no modificaría el riesgo de desarrollar la EC ni la AA y que la lactancia materna no confiere protección para EC ni para AA. Por estas razones hemos considerado de interés evaluar la evidencia disponible acerca de la EC y la AA.

Background: Active search of celiac disease (CD) among risk groups has significantly increased the scope of known clinical variants. Aim: To measure the frequency and clinical characteristics of CD among first degree relatives (FDR) of known celiac cases. Material and Methods: Between January 2012-August 2013, 37 patients with celiac disease brought 113 FDR for assessment. Their clinical data was recorded and a blood sample was obtained to measure serum Immunoglobulin A (IgA) levels, anti-transglutaminase (tTG) and anti-endomisial (EMA) antibodies. Cases with positive serology were advised to have an intestinal biopsy. Results: Fourteen relatives (12.4%) had positive serological results and none had IgA deficiency. Among IgA-tTG (-) cases, measurement of IgA/IgG-tTG identified an additional case. Two of the 14 relatives were EMA positive. All 14 cases were advised to have an intestinal biopsy, but only 6 accepted the procedure. In two, the intestinal lesion was classified Marsh ≥ 2 and active CD was diagnosed. Histology in the remaining four was Marsh 0/1 and were diagnosed potential CD, remaining under control, without gluten free diet. Conclusions: Serological prevalence of CD among first degree relatives of known celiac cases was 15 fold greater than in THE general Chilean population, strongly supporting the idea of implementing active search to customary clinical practice. Determination of IgA/IgG-tTG may be useful to improve the yield of active search. Intestinal biopsies were crucial to differentiate active classic CD from potential CD.

Remission of gastrointestinal and general symptoms after gluten withdrawal has been described in some non-celiac individuals for nearly 30 years. Only recently, efforts have been made to define this entity, now referred to as "non- celiac gluten sensitivity". It includes patients that clinically respond to gluten free diet without exhibiting allergic or autoimmune features to explain such response. Wheat allergy, celiac disease, irritable bowel syndrome and symptoms induced by high FODMAPs (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) consumption are the main differential diagnoses. The relationship with neuropsychiatric disorders such as schizophrenia and autism has not been demonstrated, but currently it gives ground to great hope in families with affected children. Epidemiology of non-celiac gluten sensitivity is not clear. It is described as more common among women and less common in children. Genetic and immune factors, changes in intestinal microbiota and non-gluten components present in wheat grains are main factors postulated in the pathogenesis of this condition. To date, there are no specific biomarkers for non-celiac gluten sensitivity and diagnosis is reached by excluding other causes of disease. A trial with gluten-free diet and subsequent gluten challenge is the methodology most frequently used to confirm diagnosis.

Knowledge about celiac disease continues to grow and amaze those who investigate, seek and treat this condition. Gone are the days when it was considered just a rare child's digestive disease. It is now recognized as a highly prevalent autoimmune condition that affects children and adults with digestive and extra-digestive symptoms of diverse intensity, disorder that may be either mono, oligo or asymptomatic from a digestive point of view. Today, it is an underdiagnosed condition, not actively considered, and often mistakes are made regarding its diagnosis, treatment and gluten-free diet monitoring. This article reviews the current definition of the disease, clinical presentations, potential patients, how to search for the disease, how the diagnosis is made and characteristics of the treatment and monitoring of celiac patients, all based on internationally agreed standards, and emphasizing those aspects that have proven to be useful in other countries regarding the management of the disease.

El conocimiento acerca de la enfermedad celíaca continúa creciendo y sorprendiendo a aquellos que la investigan, la buscan y la tratan. Lejos están los tiempos en que se la consideraba una patología digestiva del niño, poco frecuente. Actualmente se la reconoce como una condición autoinmune altamente prevalente, que afecta a niños y adultos, con manifestaciones digestivas y extra digestivas de muy diversa intensidad, pudiendo ser mono, oligo o incluso asintomática desde el punto de vista digestivo. Hoy en día está sub-diagnosticada, no se la busca activamente, se incurren en errores tanto al diagnosticarla como en la indicación del tratamiento y seguimiento de la dieta sin gluten. En este artículo revisamos la definición actual de la enfermedad, las presentaciones clínicas que se le conocen, en quiénes y cómo se debe buscar, como se hace el diagnóstico, y en qué consiste el tratamiento y seguimiento del paciente celíaco, basándonos en los criterios internacionales actualmente consensuados, y poniendo énfasis en aquellos aspectos que han demostrado ser útiles en otros países para mejorar el manejo de la enfermedad.

El perfil lipídico depende de muchos factores. Sin embargo, las variaciones estacionales de estos componentes han sido escasamente establecidas en el hemisferio sur. El objetivo de este estudio fue determinar la variación estacional del perfil lipídico por un periodo de un año en un grupo de adultos aparentemente sanos de Santiago, Chile. El diseño del estudio fue observacional y prospectivo. Participaron en el estudio 50 voluntarios sanos de ambos sexos y de edades entre 23 a 62 años. En forma mensual y durante un año se midió el perfil lipídico. LDL fue significativamente mayor en invierno y primavera que en verano (p<0,01). Por el contrario HDL disminuye en invierno (p<0,05). Se concluye que existen variaciones estacionales en los niveles séricos de LDL y HDL. El patrón circanual está caracterizado por mayores niveles de LDL en invierno y primavera y menores niveles de HDL en invierno.

The lipid profile is impacted by numerous factors. However, the seasonal variations in this profile have not been well-established in the southern hemisphere. The aim of this study was to determine the seasonal variation of the lipid profile in apparently healthy adults from Santiago, Chile. The study design was observational and prospective, involving 50 healthy volunteers of both genders, aged 23-62 years. The lipid profile was measured at monthly intervals over the course of one year. LDL was significantly higher in winter -spring than in summer- fall (p <0.01). Conversely, HDL decreases significantly in winter (p<0,05). We conclude that there are seasonal variations in the serum levels of LDL and HDL. The circannual pattern is characterized by increased levels of LDL in winter-spring and low levels of HDL in winter.

Introduction: the MYO9B gene contributes to the maintenance of the intestinal barrier and it has been postulated as a risk factor of celiac disease (CD). The objective of this study was to compare the frequency and association rs2305764, rs2305767and rs1457092 MYO09B polymorphisms in pediatric CD patients from Chile and Argentina. Patients and methods: the study was made in 104 CD pediatric patients (Chilean and Argentineans) and 104 controls subjects. MYO9B gene polymorphisms were analyzed by Taqman allelic probes. We evaluated the Hardy-Weinberg equilibrium by means of Chi-square and compared the haplotypes distribution using Fisher test. Results: SNPs rs2305767 and rs1457092 were associated with celiac disease (CD); TT genotype in rs2305767 would be a protective factor (p < 0.000, OR = 0.19 CI 0.1-0.4) and the CT genotype would be a risk factor (p < 0.0001, OR = 4.9 CI 2.2 to 11.3). CC genotype in rs1457092 also showed a protective effect for celiac (p < 0.000, OR = 0.07 CI 0.0 to 0.3). Conclusion: our findings suggest that genetic variation MYO9B gene is associated with CD, as a protective or a risk factor depending on the polymorphism studied.

Introducción: el gen miosina IX B (MYO9B) participa en el mantenimiento de la barrera intestinal y se postula que puede aportar riesgo para desarrollar enfermedad celiaca (EC). El objetivo de este estudio fue comparar la frecuencia y la asociación de los polimorfismos rs 2305764, rs 2305767 y rs 1457092 del gen MYO9B en pacientes pediátricos con EC procedentes de Chile y Argentina. Pacientes y métodos: el estudio se realizó en 104 pacientes pediátricos con EC (chilenos y argentinos) y en 104 sujetos controles. El análisis de los polimorfismos del gen MYO9B se realizó mediante ensayos Taqman de discriminación alélica. Se evalúo equilibrio de Hardy-Weinberg mediante Chi-cuadrado y comparación de haplotipos según prueba de Fisher. Resultados: los polimorfismos de un solo nucleótido (SNPs) rs2305767 y rs1457092 mostraron asociación con la EC. El genotipo TT del rs2305767 sería un factor protector (p < 0,0001, OR = 0,19 IC 0,1-0,4) mientras que el genotipo CT sería un factor de riesgo (p < 0,0001, OR = 4,9 IC 2,2-11,3). En el rs1457092, el genotipo CC resultó también un factor protector frente a esta enfermedad (p < 0,0001, OR = 0,07 IC 0,0-0,3). Conclusión: nuestros hallazgos sugieren que la variación genética del gen MYO9B estaría asociada a la EC en este grupo de pacientes, constituyendo un factor tanto de protección como a susceptibilidad dependiendo del polimorfismo en cuestión.

Background: Older subjects have a high risk of developing zinc and copper deficiencies. Aim: To determine the prevalence of copper and zinc deficiencies in adults aged over 60 years, living in Metropolitan Santiago. Subjects and Methods: Analyses were performed using anonymous serum samplesfrom older subjects living in Santiago, Chile, who participated in the multicenter project SABE. Of the studied subjects, 49.3% had enough left over serum to measure serum zinc and copper concentrations by atomic absorption spectrometry. Results: A total of444 men and 198 women were studied. A positive correlation between serum zinc and copper was found in both women (r = 0.44, p < 0.001) and men (r = 0.48, p < 0.001). There were no differences in serum zinc concentration by sex and age. The prevalence of subnormal serum zinc valúes was 66.9% in women and 66.7% in men. Women had a significantly higher serum copper valúes than men (p < 0.02) and there were no differences by age. Prevalence of subnormal serum copper valúes was higher in women than in men (32.9 and 23.7% respectively, p < 0.05). Women had significantly higher copper I zinc serum ratio than men (p < 0.001). Conclusions: Older people living in Metropolitan Santiago have a high prevalence of copper and zinc deficiencies.